Wuxi Biologics Cayman Inc 02269.HK

WuXi Biologics (Cayman) Inc. is headquartered in Wuxi, Jiangsu, China and is a global open access biologics services provider that offers comprehensive, integrated and customisable services to pharmaceutical and biotechnology companies. The company employs a team of scientists and operates a proprietary technology platform, laboratories, and cGMP-compliant manufacturing facilities.

WuXi Biologics has three operation sites located in Wuxi, Shanghai and Suzhou. In 2017, it reached a 63.5% market share in terms of revenue in China’s biologics services market. The company has so far collaborated with 13 of the 20 largest pharmaceutical companies in the world, including AstraZeneca and Genentech.
As of December 31, 2018, WuXi Biologics reported a total of 205 integrated projects, including 97 projects in the pre-clinical development stage, 94 projects in early phase (phase I and II) clinical development, 13 projects in late-phase (phase III) development and one project in commercial manufacturing.
In 2018, company revenue increased by 56.6% to RMB2,534,453 million. In 2019, the company announced its plans to expand the new integrated biologics conjugation solution centre to include commercial manufacturing in Wuxi city, China. Diversify your portfolio and buy 02269.HK stocks.